SR: Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999–2006. Angiology. 2011;62:422–429.
N: Distribution and biological effects of antimony in contaminated grassland. PhD dissertation, Sunderland Polytechnic (UK); 1988.
American Academy of Clinical Toxicology: Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42:843–854. Erratum in: J Toxicol Clin Toxicol. 2004;42:1000.
SL: Antimony poisoning—Illinois. MMWR Mortal Morbid Wkly Rep. 1964;13:250.
K: Plasmid DNA damage caused by stibine and trimethylstibine. Toxicol Appl Pharmacol. 2004;194:41–48.
Anonymous: Metals and the lung. Lancet. 1984;2:903–904.
et al.: Experimental and human studies on antimony metabolism: their relevance for the biological monitoring of workers exposed to inorganic antimony. Br J Ind Med. 1991;48:93–97.
A: Molecular basis of antimony treatment in leishmaniasis. J Med Chem. 2009;23;52:2603–2612.
F: Acute renal failure in visceral leishmaniasis treated with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1992;86:515–516.
R: Post-treatment fulminant hepatic failure in an infant with Visceral leishmaniasis: immune injury or stibogluconate toxicity? Indian J Pediatr. 2010;77:107–108.
et al.: The fate of radioactive tartar emetic administered to human subjects. J Trop Med Hyg. 1947;27:403–416.
MM: Structural requirements for chelate antidotal efficacy in acute antimony (III) intoxication. Res Commun Chem Pathol Pharmacol. 1981;32:355–363.
RP: The lesser metals. In: Oehme,
FW ed. Toxicity of Heavy Metals in the Environment, Part II. New York: Marcel Dekker; 1979:547–615.
RP: The metals: antimony. In: Clayton
FE eds. Patty’s Industrial Hygiene and Toxicology, Vol. 2. 11th ed. New York: John Wiley & Sons; 1994:1902–1913.
AP: The effect produced by antimony on the generative function. Gig Tr Prof Zabol. 1967;11:32–37.
RA: Antimony metabolites in marine algae. In: Craig
F eds. Organometallic Compounds in the Environment. Principles and Reactions. Harlow, UK: Longmans; 1988:135–37.
TG: Microbial methylation of metalloids: arsenic, antimony, and bismuth. Microbiol Mol Biol Rev. 2002;66:250–271.
A: Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch Toxicol. 2008;82:493–512.
CH: Patty’s Toxicology, Vol. 2. 5th ed. New York: John Wiley & Sons; 1994:1902–1913.
H: Recurrent episodes of thrombocytopenia during treatment with sodium stibogluconate. J Antimicrob Chemother. 1993;31:187–188.
HO: The efficacy of 2,3-dimercaptopropanol (BAL) in the therapy of poisoning by compounds of antimony, bismuth, chromium, mercury and nickel. J Pharmacol Exp Ther. 1946;87:119–125.
GH: Therapeutic conflicts and the American medical profession in the 1860s. Bull Hist Med. 1967;41:215–222.
DA: Industrial antimony poisoning. Indus Med Surg. 1954;23:521–523.
DN: Glucocorticoids as a novel approach to the treatment of disabling side effects of sodium stibogluconate. J Clin Pharm Ther. 2012;37:122–123.
BL: Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Clin Infect Dis. 1996;22:878–879.
MJ: Massive human ingestion of orpiment (arsenic trisulfide). J Emerg Med. 2013;44:367–372.
J: Factors affecting the inhibition of phosphofructokinase activity of Schistosoma mansoni by trivalent organic antimonials. Biochem Pharmacol. 1966;15:1197–1211.
PD: Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis. Trans R Soc Trop Med Hyg. 1990;84:362.
Centers for Disease Control and Prevention (CDC): Pseudo-outbreak of antimony toxicity in firefighters–Florida, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1300–1302.
S: Death from cumulative sodium stibogluconate toxicity on Kala-Azar. Clin Microbiol Infect. 2002;8:606.
H: Complexation of antimony (Sb(V)) with guanosine 5′-monophosphate and guanosine 5′-diphospho-D-mannose: formation of both mono- and bis-adducts. J Inorg Biochem. 2005;99:2257–2263.
RM: Trypanocidal activity and toxicity of antimonials. J Infect Dis. 1945;76:144–151.
M: Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg. 1985;34:702–709.
HC: Complications of kala azar and its treatment in Kenya. East Afr Med J. 1984;61:120–127.
et al.: Pneumoconiosis among workers in an antimony industry. Am J Roentgenol Radium Ther Nucl Med. 1968;103:495–508.
EM: Newer concepts in the management of environmental pulmonary edema. Angiology. 1974;25:590–601.
FD: Pulmonary edema of environmental origin. Chest. 1973;64:182–185.
ME: Effects on antimony on the cardiovascular system and intestinal smooth muscle. J Pharmacol Exp Ther. 1966;151:7–22.
A: Comparative trials of antimonial drugs in urinary schistosomiasis. Bull World Health Organ. 1968;38:197–227.
et al.: Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis. Clin Infect Dis. 1993;16:730–731.
FA: Antimony and health. BMJ. 1995;310:1216–1217.
et al.: High frequency of serious side effects from meglumine antimonate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999;61:766–769.
A: Fulminant hepatitis in an Italian infant with visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1992;86:34.
PM: The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil. Rev Soc Bras Med Trop. 2012;45:597–600.
R: The distribution and excretion of trivalent antimony in the rat following inhalation. Int Arch Gewerbepathol Gewerbehyg. 1962;19:529–545.
BG: Therapy and disease concepts: the history (and future?) of antimony in cancer. J Hist Med Allied Sci. 2002;57:61–78.
et al.: Metabolic behavior of inorganic forms of antimony in the rat. In: Proceedings of Heavy Metal in the Environmental International Conference. Heidelberg, Germany. 1983;1:1574–1577.
F: A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy. Int J Dermatol. 2010;49:295–297.
RO: Metabolism of two valence states of inhaled antimony in hamsters. Am Ind Hyg Assoc J. 1974;355:292–300.
RO: Retention of inhaled antimony-124 in the beagle dog as a function of temperature of aerosol formation. Health Phys. 1974;26:525–531.
AJ: Hamilton & Hardy’s Industrial Toxicology. Boston: John Wright PSG; 1983:13–16.
VB: Handbook on the Toxicology of Metals. 2nd ed. Amsterdam, NY: Elsevier; 1986:27–42.
T: Disruption of mannose activation in Leishmania mexicana. GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J. 2001;20:3657–3666.
N: Possible links between sickle cell crisis and pentavalent antimony. Am J Trop Med Hyg. 2012;86:1057–1061
et al.: Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis. 1994;18:83–90.
T: Arsenic and antimony: comparative approach on mechanistic toxicology. Chem Biol Interact. 1997;107:131–144.
NA, Van Dyke
HB: The tissue distribution and excretion of four organic antimonials after single or repeated administration to normal hamsters. J Pharmacol Exp Ther. 1946;87:169–180.
PO: Antimony in lung, liver and kidney tissue from deceased smelter workers. Scand J Work Environ Health. 1982;8:201–208.
R: Homoeopathy for Everyone. Harmondsworth, UK: Penguin Books; 1987.
JS: Toxicology of the Eye. 4th ed. Illinois: Charles C Thomas; 1993.
A: Antimony impairs nucleotide excision repair: XPA and XPE as potential molecular targets. Chem Res Toxicol. 2010;23:1175–1183.
et al.: Carcinogenic effects of antimony trioxide and antimony ore concentrate in rats. J Toxicol Environ Health. 1986;18:607–626.
P: Electrocardiographic changes occurring after brief antimony administration in the presence of dilated cardiomyopathy. Postgrad Med J. 1990;66:1089.
JS: The use and abuse of tartar emetic in the 19th century materia medica. Bull Hist Med. 1975;49:235–257.
et al.: Elevated antimony concentrations in commercial juices. J Environ Monit. 2010;12:822–824.
GG: The Condensed Chemical Dictionary. 10th ed. New York: Van Nostrand Reinhold; 1981:79–82.
Z: Antimony pollution in China. Sci Total Environ. 2012;421–422:41–50.
Health and Safety Executive: Antimony—Health and Safety Precautions. Guidance Note EH 19. London: HMSO; 1978.
Health and Safety Executive: Stibine—Health and Safety Precautions. Guidance Note EH12. London: HMSO; 1978.
D: Cardiac effects of sodium stibogluconate. Br J Clin Pharmacol. 1985;19:73–77.
NC: Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1993;87:691.
et al.: Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. QJM. 1994;87:465–472.
et al.: Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet. 1993;342:238–239.
L: Acute toxicity in erythroid bone marrow progenitors after antimonial therapy. Haematologica. 2001;86:1319.
et al.: Sodium stibogluconate (Pentostam) overdose during treatment of American cutaneous leishmaniasis. J Infect Dis. 1992;165:968–971.
U: Efficacy of homeopathically potentized antimony on blood coagulation. A randomized placebo controlled crossover trial. Forsch Komplementmed. 2009;16:14–18.
P: Renal tubular acidosis, a side effect of treatment with pentavalent antimony. Clin Nephrol. 1991;36:213.
DM: Practical Therapeutics. St. Louis: AMA Mosby; 1914.
A: 2,3-Dimercapto-1-propanesulphonate in heavy metal poisoning. Med Toxicol. 1987;2:317–323.
IRPTC: Antimony. In: Scientific Reviews of Soviet Literature on Toxicity and Hazards of Chemicals. Moscow, Russia: United Nations Environmental Program; 1984.
IM: Arsenic trioxide poisoning: a description of two acute overdoses. Hum Exp Toxicol. 2004;23:359–364.
RD: Survey of antimony workers. Mortality 1961-1992. Occup Environ Med. 1994;51:772–776.
et al.: Visceral leishmaniasis (kala-azar) in acquired immunodeficiency syndrome (AIDS). Dtsch Med Wochenshr. 1988;113:1920–1922.
CA: Improving the safety of intravenous admixtures: lessons learned from a Pentostam overdose. Jt Comm J Qual Patient Saf. 2006;32:366–372.
et al.: Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients. Trop Geogr Med. 1984;36:21–35.
N: Optic atrophy following repeated courses of tartar emetic for the treatment of bilharziasis. Bull Ophthalmol Soc Egypt. 1976;69:459–463.
WF: Antimony poisoning—Virginia. MMWR Mortal Morbid Wkly Rep. 1965;14:27.
et al.: External and internal antimony exposure in starter battery production. Int Arch Occup Environ Health. 1995;67:119–123.
MH: Antimony-induced cerebellar ataxia. Saudi Med J. 2006;27:90–92.
H: Speciations of antimony for the 21st century: promises and pitfalls. Trends Anal Chem. 2001;20:79–89.
E: Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol Pharmacol. 2006;69:1216–1225.
G: Characterization and metal availability of copper
, lead, antimony and zinc contamination at four Canadian small arms firing ranges. Environ Technol.
et al.: Oral antimony intoxications in man. Crit Care Med. 1990;18:324–326.
HM: Discovery of the Elements. Easton, PA: Mary Elvira Weeks; 1968:95–103.
P: A study of the distribution and fate of antimony when used as tartar emetic and fouadin in the treatment of American soldiers with schistosomiasis japonica. J Clin Invest. 1947;26:370–378.
W, Burns Ewald
DS: A 34-year-old man with intractable vomiting after ingestion of an unknown substance. Case records of the Massachusetts General Hospital. Case 22-2012. N Engl J Med. 2012;367:259–268.
BK: Hypoplasia of bone marrow secondary to sodium antimony gluconate. J Assoc Physicians India. 1990;38:310–311.
RA: Anti-bilharzial antimony drugs. Nature. 1967;214:819–820.
RI: Antimony in Medical History. Edinburgh, Scotland: Pentland Press; 1999.
RI: The industrial toxicology of antimony. The Ernestine Henry Lecture 1987. J R Coll Physicians Lond. 1989;23:28–32.
KC: Pancreatitis occurring during therapy with stibogluconate: two case reports. Clin Infect Dis. 1993;17:952–953.
WD, ed: Antimony. In: Toxicology. Chicago: Industrial Medicine; 1937:285–290.
JM: Poisoning by antimony: a case report. South Med J. 1982;75:592.
VK: Alkaloids: future prospective to combat leishmaniasis. Fitoterapia. 2009;80:81–90.
S: Contact dermatitis and contact sensitization among enamellers and decorators in the ceramics industry. Contact Dermatitis. 1993;28:59–62.
et al.: Antimony trioxide range-finding toxicity studies. OTS206062. Carnegie-Mellon Institute of Research, Carnegie-Mellon University, Pittsburgh, PA, 1978. (Sponsored by Union Carbide.)
WD: Transference studies of trace elements from cigarette tobacco into smoke condensate, and their determination by neutron activation analysis. In: Proceedings of the Tobacco Health Conference, Report 2. Lexington: University of Kentucky; 1970:37–45.
National Medical Services: 24-Hour urine antimony reference value. In: Tietz
NW ed. Textbook of Clinical Chemistry. Philadelphia: WB Saunders; 1986:1814.
MN: Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil. Trop Doct. 2009;39:180–182.
et al.: Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011;118:87–96.
R, De la Torre
J: Pentavalent antimonial-induced torsade de pointes. J Electrocardiol. 1997;30:143–145.
K: Studies on the therapy of schistosomiasis japonica. Tohoku J Exp Med. 1956;65:1–9.
R: Acute arsine poisoning in two workers cleaning a clogged drain. Arch Environ Health. 1979;34:224–227.
et al.: Trace metals in urine of United States residents: reference range concentrations. Environ Res. 1998;76:53–59.
et al.: Immunological studies of pancytopenia in visceral leishmaniasis. Isr J Med Sci. 1988;24:70–74.
M: Antimoniosis: a particular form of pneumoconiosis. I. Etiology, clinical and x-ray findings. Int Arch Occup Environ Health. 1983;51:199–207.
V: Acute renal failure and 9th, 10th nerve palsy in patient of kala-azar treated with stibnite. J Assoc Physicians India. 1994;42:338.
U: Renal dysfunction in patients of kala azar treated with sodium antimony gluconate. J Assoc Physicians India. 1994;42:383.
WT: Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet. 1980;2:226–229.
LE: Antimony poisoning in industry. AMA Arch Ind Hyg Occup Med. 1953;7:99–108.
et al.: Acute arsine intoxication as a consequence of metal burnishing operations. Am J Ind Med. 1997;32:211–216.
L: The in vitro percutaneous absorption of diantimony trioxide through human skin, unpublished report on behalf of International Antimony Oxide Industry Association, Study Number 775440, report date 20.04.2006. Charles River Laboratories, Edinburgh, UK.
M: Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore. 2008;37:916–918.
RE, de Rodriguez
JD: Efficacy and toxicity of pentostam against panamanian mucosal leishmaniasis. Am J Trop Med Hyg. 1991;44:394–398.
F: Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: insights from a new voltammetric approach. Anal Bioanal Chem. 2013;405:5201–14.
JL: Perspectives of antimony compounds in oncology. Acta Pharmacol Sin. 2008;29:881–890.
M: Contamination of bottled waters with antimony leaching from polyethylene terephthalate (PET) increases upon storage. Environ Sci Technol. 2007;41:1560–1563.
P: Antimony in the environment as a global pollutant: a review on analytical methodologies for its determination in atmospheric aerosols. Talanta. 2008;75:2–14.
SE: Uptake of antimony potassium tartrate by mouse liver slices. Br J Pharmacol. 1969;37:476–484.
I: Fundamentals of Therapy: An Extension of the Art of Healing Through Spiritual Knowledge.
4th ed. Chapters 14
, and 20
. London: Rudolf Steiner Press; 1983.
CJ: Antimony spots. Trans St Johns Hosp Derm Soc. 1965;51:40–45.
WS: Interaction of antimony tartrate with the tripeptide glutathione: implication for its mode of action. Eur J Biochem. 2000;267:5450–5457.
S: Experimental studies on antimony poisoning. Igaku Kenkyu. 1981;51:129–142.
J: Antimony toxicity. Int J Environ Res Public Health. 2010;7:4267–4277.
et al.: A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg. 1998;59:139–143.
RS: Antimony toxicity from the use of tartar emetic for the treatment of alcohol
abuse. Vet Hum Toxicol.
AS: On poisoning by tartarized antimony; with medico-legal observations on the cases of Ann Palmer and others. In: Wilks
A eds. Guy’s Hospital Reports, 3rd Series, Vol. III. London: Levy’s Hospital; 1857.
PJ: Acute intoxication from antimony trichloride. Br J Ind Med. 1966;23:318–321.
S, Garcia Salazar
MA, Jimenez Martin
MJ, Lopez Martinez
J: Torsade de pointes secondary to treatment with pentavalent antimonial drugs. Med Clin (Barc). 1998;110:717.
et al.: Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J. 1984;288:895–897.
VP: Antidotal activity of British anti-Lewisite against compounds of antimony, gold and mercury. Biochem J. 1947;41:342–346.
Van der Krogt
P: Triumph-Wagen des Antimonij (Triumphal Chariot of Antimony). A monograph on Antimony: 1604 Basilius Valentinus (1565-1624). Elementymology and Elements Multidict—Stibium. Antimony; 2003. Last update, 02/10/2003 23:39. 34. http://www.vanderkrogt.net/elements/elem/sb.html
. Accessed October 15, 2005.
PE: Physiological disposition of antimony after administration of 124Sb-labelled tartar emetic to rats, mice and monkeys, and the effects of tris (p-aminophenyl) carbonium pamoate on this distribution. Bull WHO. 1965;33:537–546.
WD: Chronic inhalation toxicity of antimony trioxide: validation of the threshold limit value. PhD dissertation. Detroit, MI: Wayne State University; 1983.
RA: The mechanism of the vomiting induced by antimony and potassium tartrate (tartar emetic). J Exp Med. 1923;37:97–111.
M: Chemical food poisoning. Q Bull Assoc Food Drug Office. 1963;27:38–45.
PO: Trace elements in serum and urine from hypertensive patients before and during treatment with chlorthalidone
. Acta Med Scand.
JS: Dermatitis in workers exposed to antimony in a melting process. J Occup Med. 1993;35:392–395.
WHO Expert Committee: The Leishmaniasis. Report of a WHO Expert Committee. World Health Organization. Technical Report Series 701. Geneva: World Health Organization; 1984.
KA: Toxicity of antimony and its compounds. Adverse Drug React Acute Poisoning Rev. 1987;6:67–90.
DN: Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travelers with New World cutaneous leishmaniasis. Negl Trop Dis. 2012;6:e1688.
JC: Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis. 1998;27:509–512.
et al.: Health risk associated with dietary co-exposure to high levels of antimony and arsenic in the world’s largest antimony mine area. Sci Total Environ. 2011;409:3344–3351.
T: Studies on antibilharzial drugs VI: the antidotal effects of sodium dimercaptosuccinate and BAL-gludoside against tartar emetic. Acta Physiol Sinica. 1957;21:24–32.
MA, Al Jaser
MH, Al Issa
R: Clinical efficacy and pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate. J Clin Pharmacol. 2010;50:1230–1237.